Biotech · Private company
Oncoceutics, Inc.
Track this companyFree. Adds Oncoceutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials9
- ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerPHASE1 · RECRUITING · started Oct 23, 2023ClinicalTrials.gov NCT05542407 · fetched Nov 12, 2026
- BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRCPHASE1_PHASE2 · TERMINATED · started Nov 15, 2019ClinicalTrials.gov NCT03791398 · fetched Nov 12, 2026
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerPHASE2 · TERMINATED · started Mar 21, 2018ClinicalTrials.gov NCT03485729 · fetched Nov 12, 2026
- ONC201 in Pediatric H3 K27M GliomasPHASE1 · TERMINATED · started Jan 25, 2018ClinicalTrials.gov NCT03416530 · fetched Nov 12, 2026
- ONC201 in Adults With Recurrent H3 K27M-mutant GliomaPHASE2 · TERMINATED · started Oct 30, 2017ClinicalTrials.gov NCT03295396 · fetched Nov 12, 2026
- Single Agent ONC201 in Recurrent or Metastatic Endometrial CancerPHASE2 · TERMINATED · started Jun 8, 2017ClinicalTrials.gov NCT03099499 · fetched Nov 12, 2026
- Oral ONC201 in Relapsed/Refractory Multiple MyelomaPHASE1_PHASE2 · TERMINATED · started Apr 19, 2017ClinicalTrials.gov NCT02863991 · fetched Nov 12, 2026
- Oral ONC201 in Adult Recurrent GlioblastomaPHASE2 · TERMINATED · started Jan 1, 2016ClinicalTrials.gov NCT02525692 · fetched Nov 12, 2026
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromePHASE1_PHASE2 · TERMINATED · started Nov 3, 2015ClinicalTrials.gov NCT02392572 · fetched Nov 12, 2026